This Reishi mushroom cancer study explored whether Ganopoly, a polysaccharide extract from Ganoderma lucidum, could improve immune function in advanced-stage cancer patients. Researchers conducted a 12-week clinical trial to test how this traditional medicinal mushroom might enhance immunity and reduce inflammation.
Study Overview
Published in: Immunological Investigations
Study Type: Clinical trial
Participants: 34 advanced-stage cancer patients
Duration: 12 weeks
Intervention: 1800 mg Ganopoly, three times daily before meals
Key Findings from the Reishi Mushroom Cancer Study
The results suggest that Ganopoly, a Reishi mushroom extract, has significant immune-modulating effects:
Increased immune signaling: Levels of IL-2, IL-6, and IFN-γ rose significantly.
Reduced inflammation: IL-1 and TNF-α concentrations decreased.
Enhanced immune cells: Natural killer (CD56+) cells increased significantly; CD3+, CD4+, and CD8+ cells rose slightly.
Improved immune response: Patients showed stronger PHA responses and higher NK cell activity.
Why This Reishi Study Matters for Immunity
For patients with advanced cancer, immune suppression and chronic inflammation pose major challenges. This Reishi mushroom cancer study suggests that Ganopoly may help:
Strengthen natural immune defenses
Balance inflammatory responses
Support integrative cancer care alongside conventional treatments
By enhancing immune activity, Reishi mushrooms continue to bridge traditional medicine and modern science.
Final Thoughts
Medicinal mushrooms like Reishi are gaining global attention for their adaptogenic and immune-supportive properties. This Ganopoly clinical trial adds to the growing body of evidence showing how Ganoderma lucidum may offer real-world benefits for patients facing serious health conditions.
